Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
1(17%)
Results Posted
100%(2 trials)
Terminated
3(50%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_3
1
17%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
40.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

completed233%
active_not_recruiting117%
terminated350%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruitingphase_1

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

NCT03641755
completedphase_3

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01303796
terminatedphase_2

A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

NCT00476554
terminatedphase_2

A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer

NCT00885963
completedphase_1

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

NCT00380653
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03641755Phase 1

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Active Not Recruiting
NCT01303796Phase 3

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed
NCT00476554Phase 2

A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

Terminated
NCT00885963Phase 2

A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer

Terminated
NCT00380653Phase 1

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

Completed
NCT01253460Phase 2

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6